Ymmunobio

Yimmunobio AG is a preclinical oncology biotechnology company focused on developing innovative treatments for cancer patients through novel antibodies. These therapies have significant market potential and broad applicability in solid tumors. Yimmunobio has made extensive progress in developing first-in-class or novel antibodies that have the potential to overcome resistance to existing treatments in cancer patients.